Cardiogen
Cardiogen is a synthetic short peptide sold as a cardiac-tissue-targeted "bioregulator" in the Khavinson organotropic-peptide tradition, but no peer-reviewed clinical or animal study of this specific product could be located in PubMed/PMC-indexed literature.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Cardiogen is marketed as a tetrapeptide (reported by its manufacturer as an Ala-Glu-Asp-Arg-type sequence) built on the Khavinson-school hypothesis that very short peptides can enter cells, interact with chromatin, and modulate transcription of genes in the tissue type from which the parent peptide complex was originally derived — in this case cardiac tissue. This "organotropic" gene-regulation model is drawn from in vitro and animal work on other short peptides in the same family (e.g., effects on proliferative and inflammatory signaling in cultured monocyte/macrophage cells), not from direct study of Cardiogen itself. No mechanistic data specific to this peptide's action on cardiomyocytes or vascular tissue were found in indexed literature.
Typical results seen in research
There is no dedicated clinical trial, cohort study, or animal study of Cardiogen under this name in PubMed or PMC. Broader reviews of the Khavinson short-peptide/bioregulator class report improvements in aging biomarkers and reduced mortality in small, largely non-blinded Russian cohort studies of related (but different) peptide preparations, and general claims of cardioprotective and anti-aging activity are extrapolated from this wider body of work rather than from evidence on this compound specifically. Overall, any claimed cardiovascular benefit of Cardiogen itself should be treated as unproven and based on analogy, not direct evidence.
How it’s commonly used
Cardiogen is typically taken orally as a capsule or tablet, often as part of a rotating stack with other Khavinson-tradition tissue-specific bioregulators used for general longevity and cardiovascular-support purposes. It is not an approved medical therapy and is used almost exclusively in a self-directed research/longevity-supplement context rather than under clinical supervision.
- Biogerontology · 2010 Peptide bioregulation of aging: results and prospects
- Adv Gerontol · 2012 [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]
- Adv Gerontol · 2013 [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]
- Int J Mol Sci · 2022 Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.